MetaVia to Present at the Emerging Growth Conference in December
MetaVia (Nasdaq: MTVA), a clinical-stage biotechnology company specializing in cardiometabolic diseases, has announced its participation in the upcoming Emerging Growth Conference. The company's President and CEO Hyung Heon Kim, along with CFO Marshall H. Woodworth, will deliver a company update on December 4, 2024, at 4:10 pm ET.
The presentation will include a Q&A session, with attendees able to submit questions either in advance via email or during the event. Interested parties can register online to attend the virtual conference, with additional opportunities available for private management meetings.
MetaVia (Nasdaq: MTVA), una compagnia biotecnologica in fase clinica specializzata nelle malattie cardiometaboliche, ha annunciato la sua partecipazione alla prossima Emerging Growth Conference. Il Presidente e CEO della compagnia, Hyung Heon Kim, insieme al CFO Marshall H. Woodworth, forniranno un aggiornamento aziendale il 4 dicembre 2024, alle 16:10 ET.
La presentazione comprenderà una sessione di domande e risposte, con i partecipanti che potranno inviare domande in anticipo via email o durante l'evento. Le parti interessate possono registrarsi online per partecipare alla conferenza virtuale, con ulteriori opportunità disponibili per meeting privati con il management.
MetaVia (Nasdaq: MTVA), una compañía biotecnológica en etapa clínica especializada en enfermedades cardiometabólicas, ha anunciado su participación en la próxima Emerging Growth Conference. El Presidente y CEO de la compañía, Hyung Heon Kim, junto con el CFO Marshall H. Woodworth, ofrecerán una actualización de la empresa el 4 de diciembre de 2024, a las 4:10 pm ET.
La presentación incluirá una sesión de preguntas y respuestas, donde los asistentes podrán enviar preguntas por adelantado a través de correo electrónico o durante el evento. Las partes interesadas pueden registrarse en línea para asistir a la conferencia virtual, con oportunidades adicionales disponibles para reuniones privadas con la dirección.
MetaVia (Nasdaq: MTVA)는 심혈관 대사 질환을 전문으로 하는 임상 단계의 생명공학 회사로, 다가오는 Emerging Growth Conference에 참가할 것임을 발표했습니다. 회사의 대표이사인 Hyung Heon Kim과 CFO인 Marshall H. Woodworth는 2024년 12월 4일, 오후 4시 10분 ET에 회사 업데이트를 발표할 예정입니다.
발표에는 질의응답 시간이 포함되며, 참석자들은 사전 이메일을 통해 또는 행사 중 질문을 제출할 수 있습니다. 관심 있는 분들은 온라인으로 가상 회의에 참석하기 위한 등록이 가능하며, 경영진과의 비공식 미팅 기회도 추가로 제공됩니다.
MetaVia (Nasdaq: MTVA), une entreprise de biotechnologie en phase clinique spécialisée dans les maladies cardiométaboliques, a annoncé sa participation à la prochaine Emerging Growth Conference. Le Président et PDG de l'entreprise, Hyung Heon Kim, ainsi que le CFO Marshall H. Woodworth, fourniront une mise à jour de l'entreprise le 4 décembre 2024 à 16h10 ET.
La présentation inclura une session de questions-réponses, où les participants pourront soumettre des questions soit à l'avance par e-mail, soit durant l'événement. Les parties intéressées peuvent s'inscrire en ligne pour assister à la conférence virtuelle, avec des opportunités supplémentaires disponibles pour des réunions privées avec la direction.
MetaVia (Nasdaq: MTVA), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf kardiometabolische Erkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden Emerging Growth Conference angekündigt. Der Präsident und CEO des Unternehmens, Hyung Heon Kim, sowie CFO Marshall H. Woodworth werden am 4. Dezember 2024 um 16:10 Uhr ET ein Unternehmensupdate präsentieren.
Die Präsentation umfasst eine Frage-und-Antwort-Runde, in der die Teilnehmer Fragen im Voraus per E-Mail oder während der Veranstaltung stellen können. Interessierte Parteien können sich online registrieren, um an der virtuellen Konferenz teilzunehmen, und es stehen zusätzliche Möglichkeiten für private Führungstreffen zur Verfügung.
- None.
- None.
After the presentation, MetaVia management will open the floor for questions. Please submit your questions in advance to questions@emerginggrowth.com, or ask your questions during the event.
Please register using this link to attend the virtual conference and receive any updates that are released. To schedule a meeting with management outside of the conference, please contact Michael Miller at mmiller@rxir.com.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.
For more information, please visit www.metaviatx.com.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-to-present-at-the-emerging-growth-conference-in-december-302317541.html
SOURCE MetaVia Inc.
FAQ
When is MetaVia (MTVA) presenting at the Emerging Growth Conference?
How can investors submit questions for MetaVia's (MTVA) presentation?
Who will be presenting at the December 2024 Emerging Growth Conference for MetaVia (MTVA)?
How can investors attend MetaVia's (MTVA) presentation at the Emerging Growth Conference?
